AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, has enrolled the first patient in its Phase 1 clinical trial assessing the safety and tolerability of AP-101, an experimental therapy for amyotrophic lateral sclerosis (ALS). AP-101 is a human…

Collaborative Medicinal Development (CMD) has enrolled the first patient in its Phase 2/3 clinical trial assessing the safety and efficacy of CuATSM, an investigational therapy for amyotrophic lateral sclerosis (ALS). The trial (NCT04082832) is aimed at evaluating the efficacy and safety of CuATSM. The…

Mexiletine, an oral medicine to treat irregular heartbeats, is safe and effective for reducing muscle cramps in patients with amyotrophic lateral sclerosis (ALS), results from a Phase 4 clinical trial show. To date, this is the only treatment shown to reduce both the number and intensity of cramps…

A Harvard Medical School professor and scientist, Sabrina Paganoni, has won the 2019 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Scientific Impact Award for her work in a Phase 2a trial testing fingolimod as a potential treatment for amyotrophic lateral sclerosis (ALS). Fingolimod is marketed as Gilenya (by Novartis), an…

The experimental treatment SBT-272 delayed the onset of neurological symptoms, lowered levels of a biomarker of nerve damage, and prolonged the life of male mice in a model of amyotrophic lateral sclerosis (ALS). Stealth BioTherapeutics, the company developing SBT-272, also announced plans to open a Phase 1…

Experimental treatment reldesemtiv appears to reduce functional deterioration in patients with fast progressing amyotrophic lateral sclerosis (ALS), a new analysis of the FORTITUDE-ALS trial shows. The additional analyses were presented by the trial’s principal investigator, Jeremy M. Shefner, MD, PhD, a professor at the Barrow Neurological Institute…

The U.S. Department of Defense (DoD) has issued a two-year research grant totaling $758,121 to support a group of scientists from the University of Arizona Health Sciences Center for Innovation in Brain Science (CIBS) working on the development of RASRx1902, a potential treatment for amyotrophic lateral sclerosis…

My heart ached for my kids after my husband, Todd, was diagnosed with amyotrophic lateral sclerosis (ALS). Isaac was 9 months old and Sara was 4. How would ALS affect them? I had no idea how to help them navigate our future. A year after Todd was diagnosed, I…

The Chan Zuckerberg Initiative (CZI) has awarded I AM ALS a $453,000 grant to develop ways to connect amyotrophic lateral sclerosis (ALS) stakeholders and the public in the fight against ALS and other rare disorders. As part of CZI’s wider effort to accelerate investigations into rare diseases,…

In contrast to what is often assumed, new research suggests that clumps of the protein TDP-43 — a hallmark of amyotrophic lateral sclerosis (ALS) — actually protect nerve cells rather than harm them. If this finding confirmed in future studies, it could hugely impact how ALS and other neurodegenerative diseases…